Successful treatment with canakinumab of a paediatric patient with resistant Beh&#231;et&apos;s disease by I. Pagnini et al.
Letters to the Editor
Rheumatology 2015;54:13271328
doi:10.1093/rheumatology/kev197
Advance Access publication 19 May 2015
Successful treatment with canakinumab of a
paediatric patient with resistant Behc¸et’s disease
SIR, Behc¸et’s disease (BD) is a systemic vasculitis char-
acterized by a wide clinical spectrum including recurrent
oral and genital ulceration, uveitis, vascular, neurological,
articular, renal and gastrointestinal manifestations [1].
Treatment of BD depends on the clinical manifestation
and organ involvement. Although colchicine, NSAIDs
and topical steroids are often sufficient for mucocuta-
neous and joint involvement, a more aggressive approach
with immunosuppressive drugs is necessary for severe
manifestations such as posterior uveitis, retinal vasculitis,
recurrent fevers, vascular, neurological and gastrointes-
tinal involvement. However, some patients still have
refractory disease, flares or irreversible organ damage.
Recent advances in the study of pathogenic mechanisms
have enabled the identification of new potential targets
and future biologic therapies for BD. In contrast to current
non-specific immunosuppressive agents, often used
empirically, the emergence of biotherapies provides the
possibility of interfering with specific pathogenic path-
ways and appears to promise treatments for patients
with refractory or relapsing BD [1].
We describe a child with juvenile BD with recurrent
fevers, oral and genital ulceration, skin lesions, arthralgia
and abdominal pain, who was unsuccessfully treated with
a range of immunosuppressive drugs and biotherapies.
He achieved clinical remission only with canakinumab, a
fully human anti-IL-1 b antibody.
A 9-year-old Caucasian boy was diagnosed as having
BD at the age of 5 years, based on typical clinical mani-
festations. When he was 2 years old, he had started to
complain of constipation, abdominal pain and encopresis,
associated with recurrent oral ulceration, skin lesions
(papulopustolar with ulcers, especially on the face) and
photophobia. Two years later he presented with recurrent
fevers, genital ulceration and headaches. Laboratory tests
showed mild anaemia (haemoglobin 11.7 g/dl), normal
ESR and CRP level, and positivity for HLA-B51. Coeliac
disease screening, ANA, ANCA, anti-Saccharomyces cer-
evisiae antibodies, aCL, anti-b2-glycoprotein antibodies
and faecal calprotectin were all negative. A barium
enema showed dolichocolon and diffuse hypokynesia of
the large bowel. Gastrointestinal endoscopy and brain
MRI were normal. A pathergy test was also performed
and resulted positive after 48 h. Uveitis was excluded by
ophthalmological examination.
A diagnosis of BD was made in October 2010 and treat-
ment with colchicine (initially at the dosage of 0.25 mg/
day, after 4 months increased to 0.5 mg/day) and prednis-
one 15 mg/day was commenced. After a few months, due
to persistent oral and skin ulceration, associated with con-
stipation, abdominal pain, arthralgia, recurrent fever and
headache, the colchicine was interrupted and thalidomide
50 mg/day was added to the prednisone (0.5 mg/kg/day).
Three months later, clinical symptoms were still present,
so MMF 250 mg twice a day was substituted for the thal-
idomide. However, clinical improvement was still not
reached after another 4 months; therefore, biotherapy
with adalimumab (24 mg/m2 every 2 weeks) was started
in association with the MMF. Quite quickly, the fever,
headache, abdominal pain and oral ulceration dis-
appeared, but after a few months all systemic clinical fea-
tures reappeared. So, adalimumab and MMF were
stopped and anakinra (2 mg/kg) was introduced, initially
at the dosage of 2 mg/kg/day, increased to 4 mg/kg/day,
with only partial benefit. Oral and skin ulceration, recurrent
fever, arthralgia, headaches and abdominal pain were in
fact still present, associated with a persistent increase in
inflammatory markers and mild anaemia. Thus, after
19 months of treatment with anakinra we switched to
canakinumab, at a dose of 4 mg/kg every 28 days.
After 4 months of this therapy, complete clinical and
laboratory remission was obtained. Of note, steroid treat-
ment was gradually reduced to 5 mg/day. At the last
follow-up (6 months after the first dose) the boy was com-
pletely asymptomatic.
BD is often difficult to treat, and requires biologic treat-
ment in cases with severe systemic involvement. Initially,
TNF inhibitor was used successfully, but resistant cases
exist and hence other biologics have been tried.
Canakinumab is a human mAb targeted at IL-1b that
has been shown to be effective in various autoinflamma-
tory syndromes such as cryopyrin-associated periodic
syndrome and systemic JIA [2, 3]. Anakinra, a recombin-
ant, non-glycosylated human IL-1 receptor antagonist,
has been used in patients with BD refractory to conven-
tional treatments [4]; and gevokizumab, a recombinant
humanized anti-IL-1b antibody, was used in seven BD
patients with resistant uveitis and retinal vasculitis [5].
Interestingly, our patient did not respond to anakinra,
but benefited from canakinumab. Both agents are IL-1
blockers, but anakinra blocks IL-1a and IL-1b and has a
short half-life (46 h), while canakinumab specifically
targets IL-1b and has a longer half-life. To our knowledge,
there are only a few published reports of BD patients
treated with canakinumab: three adults [6, 7] and a
16-year-old girl [8].
To our knowledge our case is, therefore, the
youngest reported so far. Although more studies are
necessary to confirm the efficacy and safety of canakinu-
mab in paediatric patients with persistent systemic
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features, we think that canakinumab may be effective in
the treatment of refractory BD and that a clinical trial is
warranted.
Rheumatology key message
. Canakinumab can be effective in paediatric patients
with refractory Behc¸et’s disease.
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Comment on: The validation of a diagnostic rule
for gout without joint fluid analysis: a prospective
study
SIR, Ideally, diagnosing a disease implies recognizing its pos-
sibility under all the forms in which it can present; being able
to distinguish it from other diseases that can share a similar
presentation; and also ascertaining that all diagnoses are
correct. Fortunately this is possible in gout, a disease result-
ing from the deposition of MSU crystals in the surface of the
articular cartilage and other tissues. The crystals are easily
identifiable by microscopy in the SF of joints stricken by gout
attacks and also in asymptomatic joints previously inflamed
[1] if the patient has not been treated with urate-lowering
drugs; also the crystals can be detected by needling a
tophus. Although US is not yet at the level of providing an
accurate diagnosis it allows the location of crystal aggre-
gates or inflammation in joints less suitable for blind arthro-
centesis, thus allowing them to be sampled for crystal
analysis. In a proper setting, unequivocal gout diagnosis ap-
pears to be always possible with few exceptions.
It is against this background that Kienhorst et al. [2]
published in Rheumatology a clinical diagnostic tool for
gout. In a recent editorial [3] we highlighted the shortcom-
ings of this approach for gout diagnosis, the key mes-
sages being that clinical recognition relies on the clinical
skills and interests of the diagnosing physician, which
allow him or her to properly interpret the clinical features
encountered; diagnostic rules built mainly on typical fea-
tures will hamper the detection of those not included
in these features; and the purpose of the developed cri-
teria should be clearly stated to avoid their use in settings
different from that for which they were built.
Gout diagnosis and management by general phys-
icians and even by rheumatologists is still far from opti-
mal [4], and a diagnosis based on crystal identification
remains underused and substituted by clinical
approaches. Even the landmark clinical manifestation of
gout—podagra—can result from other conditions such
calcium pyrophosphate crystals, PsA or local problems
when arthrocentesis is applied [5]. In the study by
Kienhorst et al. [2] only patients with acute monoarthritis
were enrolled to validate their tool. The authors felt confi-
dent that this tool would also work well for patients with
oligo or polyarthritis, but—as they discuss—did not test it.
The absence of crystal-proven series of gout means the
exact frequency of patients with less characteristic clinical
features is ignored and for sure, approaches such as the
one developed by Kienhorst et al. [2] contribute to
sustaining the idea of gout as a disease restricted to its
paradigmatic clinical features. The 2007 EULAR recom-
mendations [6] outline that ‘For typical presentations of
gout (such as recurrent podagra with hyperuricaemia)
a clinical diagnosis alone is reasonably accurate but not
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